DYNAMICS OF LEPTIN, SOLUBLE LEPTIN RECEPTORS, FREE LEPTIN INDEX AND RESISTIN IN REDUCING BODY WEIGHT IN PATIENTS WITH ARTERIAL HYPERTENSION ASSOCIATED WITH OBESITY

Objective. To investigate the role of leptin, its soluble receptors, free leptin index and resistin in development of metabolic syndrome (MS) and to estimate the efficiency of a diet modification. design and methods. Altogether 90 patients with arterial hypertension (HTN) 1–2 degrees without any preceding antihypertensive therapy were enrolled: a group of obese subjects (n = 70), patients without obesity (n = 20); 25 normotensive patients with obesity but without other metabolic disturbances; 30 almost healthy individuals (average age — 48,2 ± 2,4 years). Insulin level, HOMA-IR, leptin, leptin receptors, resistin, free leptin index (FLI = leptin × 100/sLR).) were determined. All patients had followed a diet for 6 months.

Results. The leptin, FLI, НОМА-IR and resistin levels were higher, while sLR was lower in MS group compared to controls. In the group of patients with HTN without obesity a significant increase in the resistin level was found compared to normotensive subjects. The FLI was directly related to triglyceride (R = 0,42; р = 0,04), uric acid levels (R = 0,39; р = 0,03), and LDL levels (R = 0,39; р = 0,03), and HOMA-IR (R = 0,42; р = 0,04). Resistin correlated with blood pressure (R = 0,36; р = 0,04), triglycerides (R = 0,42; р = 0,04), and HOMA-IR (R = 0,37; р = 0,04).

Conclusions. Blood pressure in obese patients is associated with increased level of resistin, leptin resistance and low plasma level of soluble leptin receptors. The free leptin index is a more accurate marker for leptin resistance. The resistin can be considered as an unfavorable marker of metabolic disturbances in hypertensive patients, regardless of the presence of obesity.

1. Лупанов В. П. Ожирение как фактор риска развития сердечно-сосудистых катастроф. Русский медицинский журнал. 2003;6:331. [Lupanov VP. Obesity is a cardiovascular risk factor. Russkij Meditsinskij Zhurnal = Russian Medical Journal. 2003;6:331. In Russian].

2. Александров А. А., Шацкая О. А., Кухаренко С. С., Ядрихинская М. Н., Абдалкина Е. Н., Дроздова Е. Н. и др. Резистин и диабетическая кардиомиопатия: патогенетические взаимосвязи. Consilium medicum. 2014;16 (10):109–116. [Aleksandrov AA, Shackaya OA, Kuharenko SS, Yadrikhinskaya MN, Abdalkina EN, Drozdova EN et al. Resistin and diabetic cardiomyopathy: pathogenetic relationship. Consilium medicum. 2014;16(10):109–116. In Russian].

3. Завражных Л. А., Смирнова Е. Н. Значение психологических характеристик пациента для эффективного лечения метаболического синдрома. Клиницист. 2011;5(3):49–55. doi:10.17650/1818–8338–2011–3-49–54. [Zavrazhnykh LA, Smirnova EN. The importance of psychological characteristics of the patient for the effective treatment of metabolic syndrome. Klinitsist = The Clinician. 2011;5(3):49–54. doi: 10.17650/1818–8338–2011–3-49–54. In Russian].

4. Вербова А. Ф., Митрошина Е. В. Адипокины и сердечнососудистая система. Эндокринология. Новости, мнения, обучение. 2014;2:5–7. [Verbova AF, Mitroshina EV. Adipokines and cardiovascular system. Endocrinology. Novosti, Mneniya, Obucheniye = News, opinions, education. 2014;2;5–7. In Russian].

5. Коваренко М. А., Руяткина Л. А., Петрищева М. С., Бодавели О. В. Лептин: физиологические и патологические аспекты действия. Вестник НГу. Серия: Биология, клиническая медицина. 2003;1(1):59–74. [Kovarenko MA, Ruyatkina LA, Petrishcheva MS, Bodaveli OV. Leptin: physiological and pathological aspects of functioning. Vestnik NGU = NSU Bulletin. Series: Biology, Clinical Medicine. 2003;1(1):59–74. In Russian].

6. Бунова С. С. Динамика изменений нейрогуморального профиля и формирование метаболических нарушений у больных артериальной гипертензией в зависимости от массы тела. Вестник Санкт-Петербургского университета. 2009;1:11–18. [Bunova SS. Dynamics of changes in neurohumoral profile and formation of metabolic disorders in patients depending on body weight. Vestnik Sankt-Peterburgskogo Universiteta = Bulletin of St. Petersburg State University. 2009;1:11–18. In Russian].

7. El-Haschimi K, Pierroz DD, Hileman SM, Bjørbaek C, Flier JS. Two defects contribute to hypothalmic leptin resistance in mice with diet-induced obesity. J Clin Invest. 2000;105(12):1827–32.

8. Stępień M, Wlazeł RN, Paradowski M, Banach M, Rysz M, Misztal et al. Serum concentrations of adiponectin, leptin, resistin, ghrelin and insulin and their association with obesity indices in obese normoand hypertensive patients — pilot study. J Am Soc Nephrol. 2010;21(7):1185–1191: doi: 10.1681/ASN.2009101053

9. Koh KK, Park SM, Quon MJ. Leptin and cardiovascular disease. Circulation. 2008;117(25):3238–3249. doi: 10.1161

10. Kratzsch J, Lammert A, Bottner A, Seidel B, Mueller G, Thiery J et al. Circulating soluble leptin receptor and free leptin index during childhood, puberty, and adolescence. J Clin Endocrinol Metab. 2002;87(10):4587–94.

11. Lieb W, Sullivan LM, Harris TB, Roubenoff R, Benjamin EJ, Levy D et al. Plasma leptin levels and incidence of heart failure, cardiovascular disease, and total mortality in elderly individuals. Diabetes Care. 2009;32(4):612–616. doi: 10.2337/dc08–1596

12. Holm JC, Gamborg M, Ward LC, Gammeltoft S, Kaas-Ibsen K, Heitmann BL et al. Tracking of leptin, soluble leptin receptor, and the free leptin index during weight loss and regain in children. Obes Facts. 2011;4(6):461–468 doi: 10.1159/000335121